



- 5

Provided herein are compounds of formula I:



(1)

R^A is selected from the group consisting of:




10


s is 0 or 1;

is not halogen, cyano, or a C₁-C₆ alkoxy, C₁-C₆ haloalkoxy or C₁-C₆ thioalkyl having an oxygen or sulfur atom directly bonded to the nitrogen atom;


R^{B2} is selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl, C₁-C₆ alkyl-N(R^N)₂, phenyl, benzyl, CH₂-(C₃-C₆ cycloalkyl), CH₂CH₂-(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl), CH₂CH₂-(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH₂-(5 to 6 membered heteroaryl); wherein when R^{B2} is phenyl or benzyl the phenyl ring is optionally substituted by 1 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano;

10 provided that, when R^A is  and R^{2a} and R^{2b} are each hydrogen, R¹ is not hydrogen, halogen or methyl; and

further provided that, when the B ring is substituted by C₁-C₆ alkyl-N(R^N)₂ and phenyl, and each R^N is


hydrogen,  is not methyl, tert-butyl, N-ethylmorpholino, or methoxyethyl.

In one aspect, provided herein is a compound of formula (I):



or a pharmaceutically acceptable salt thereof, wherein:

R^A is selected from the group consisting of:



s is 0 or 1;

R^1 is selected from the group consisting of hydrogen, deuterio, fluoro, hydroxyl, cyano, C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, C_1 - C_6 alkyl substituted with one $(R^N)_2N$ substituent, C_1 - C_6 cyanoalkyl, C_1 - C_6 alkylsulfonyl, phenyl, benzyl, 4 to 6 membered heterocyclyl, and 5 to 6 membered heteroaryl;

wherein, when R¹ is phenyl, benzyl, C₁-C₆ alkyl, C₁-C₆ alkoxy or C₃-C₆ cycloalkyl, the phenyl ring of the phenyl or the benzyl, the alkyl of the C₁-C₆ alkyl or the C₁-C₆ alkoxy, or the cycloalkyl ring of the C₃-C₆ cycloalkyl is optionally substituted with 1 to 2 substituents selected from the group consisting of fluoro, chloro, cyano, C₁-C₃ alkyl, cyclopropyl, C₁-C₃ alkoxy, C₁-C₃ hydroxyalkyl, C₁-C₃ haloalkyl, C₁-C₆ alkoxy-carbonyl, C₁-C₃ alkoxy-C₁-C₃ alkyl and C₁-C₃ haloalkoxy;

R^{2a} and R^{2b} are each independently selected from the group consisting of hydrogen, deuterio, fluoro, hydroxyl, C₁-C₃ alkyl, and C₁-C₃ fluoroalkyl; provided that both R^{2a} and R^{2b} cannot be hydroxyl; or


R¹ is selected from the group consisting of hydrogen, deuterio, fluoro, methyl, and cyano; and

R^{2a} and R^{2b} together with the carbon atom to which they are both attached form a 4 to 6 membered heterocyclic ring or a 3 to 5 membered carbocyclic ring, each optionally substituted by 1 to 2 substituents selected from the group consisting of fluoro, chloro, hydroxyl, cyano, C₁-C₃ alkyl, hydroxymethyl, methoxymethyl, C₁-C₄ alkoxy-carbonyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy;

each R^N is independently selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkyl; or two R^N together with the nitrogen atom to which they are both attached form a 4-6 membered heterocyclic ring;

each R⁶ is independently selected from the group consisting of hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ cyanoalkyl, C₁-C₃ alkyl-carbonyl, C₁-C₃ methylsulfonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, formyl, C₁-C₆ haloalkoxy, cyano, 1-methyl-pyrazol-4-yl and pyrimidinyl;

the A ring, the B ring, R^{B1}, R^{B2}, q and p together are selected from the group consisting of:




R^{3a} and R^{3b} are selected as follows:

one of R^{3a} and R^{3b} is H, and the other is selected from the group consisting of hydrogen, deuterio, fluoro, chloro, hydroxyl, cyano, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, cyclopropyl, C_1 - C_4 alkoxy and C_1 - C_4 haloalkoxy; or

each of R^{3a} and R^{3b} is independently selected from the group consisting of deuterio, fluoro, chloro, hydroxyl, cyano, and methyl, provided that R^{3a} and R^{3b} cannot both be OH or CN; or

R^{3a} and R^{3b} , together with the carbon atom to which they are both attached, form 1,1-cyclopropylene; and

R^4 is selected from the group consisting of C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkoxy, C_1 - C_6 thioalkyl, phenyl, benzyl, CH_2 -(C_3 - C_6 cycloalkyl), CH_2CH_2 -(C_3 - C_6 cycloalkyl), CH_2 -(4 to 6 membered heterocyclyl), CH_2CH_2 -(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH_2 -(5 to 6 membered heteroaryl); wherein when a phenyl ring or a 5 to 6 membered heteroaryl is present it may be substituted by 1 to 3 substituents selected from the group consisting of halogen, C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_1 - C_4 alkoxy, C_1 - C_4 haloalkoxy, and cyano;

provided that, when R^A is  and R^{2a} and R^{2b} are each hydrogen, R^1 is not hydrogen, halogen or methyl.

Also provided herein are pharmaceutical compositions comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients. In another aspect, there is provided a pharmaceutical composition comprising a compound as defined herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Specific embodiments include pharmaceutical compositions suitable for oral delivery.

Also provided herein are oral formulations of a compound of formula I, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or excipients suitable for oral delivery.

Also provided herein are methods of treatment of diseases and disorders associated with inflammation, cell death, and others related to RIP1 kinase, as described further below.

Also provided herein are compounds or pharmaceutical compositions for use as therapeutically active substances. In another aspect, there is provided a compound as defined herein, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition as defined herein, for use as a therapeutically active substance. In another aspect, there is provided a compound as defined herein, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition as defined herein, for use in the treatment of a disease or disorder selected from the group consisting of Parkinson's Disease, Lewy body dementia, multiple system atrophy, Parkinson-plus syndrome, tauopathy, Alzheimer's Disease, frontotemporal dementia, amyotrophic lateral sclerosis, spinal muscular atrophy, primary lateral sclerosis, Huntington's disease, ischemia, stroke, intracranial hemorrhage, cerebral hemorrhage, muscular dystrophy, progressive muscular atrophy, pseudobulbar palsy, progressive bulbar palsy, spinal muscular atrophy, inherited muscular atrophy, peripheral neuropathy, progressive supranuclear palsy, corticobasal degeneration, and demyelinating disease.

Also provided herein are uses of compounds or pharmaceutical compositions for use in the treatment of diseases and disorders associated with inflammation, cell death, and others related to RIP1 kinase, as described further below.


Also provided herein are uses of compounds or pharmaceutical compositions for the preparation of a medicament for the treatment of diseases and disorders associated with inflammation, cell death, and others related to RIP1 kinase, as described further below. In another aspect, there is provided use of a compound as defined herein, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition as defined herein, in the preparation of a medicament for the treatment of a disease or disorder selected from the group consisting of Parkinson's Disease, Lewy body dementia, multiple system atrophy, Parkinson-plus syndrome, tauopathy, Alzheimer's Disease, frontotemporal dementia, amyotrophic lateral sclerosis, spinal muscular atrophy, primary lateral sclerosis, Huntington's disease, ischemia, stroke, intracranial hemorrhage, cerebral hemorrhage, muscular dystrophy, progressive muscular atrophy, pseudobulbar palsy, progressive bulbar palsy, spinal muscular atrophy, inherited muscular atrophy, peripheral neuropathy, progressive supranuclear palsy, corticobasal degeneration, and demyelinating disease.

Also provided herein are compounds or pharmaceutical compositions for use in the treatment of diseases and disorders associated with inflammation, cell death, and others related to RIP1 kinase, as described further below.

Also provided herein are uses of compounds or pharmaceutical compositions for use in the treatment of diseases and disorders associated with inflammation, cell death, and others related to RIP1 kinase, as described further below.

Also provided herein are uses of compounds or pharmaceutical compositions for the preparation of a medicament for the treatment of diseases and disorders associated with inflammation, cell death, and others related to RIP1 kinase, as described further below.

In another aspect, there is provided a compound of formula (II):



or pharmacologically acceptable salt thereof.

DETAILED DESCRIPTION OF THE INVENTION


DEFINITIONS

As provided herein, all chemical formulae and generic chemical structures should be interpreted to provide proper valence and chemically stable bonds between atoms as understood by one of ordinary skill in the art. Where appropriate, substituents may be bonded to more than one adjacent atom (e.g., alkyl includes methylene where two bonds are present).


In the chemical formulae provided herein, “halogen” or “halo” refers to fluorine, chlorine, and bromine (*i.e.*, F, Cl, Br).

Alkyl, unless otherwise specifically defined, refers to an optionally substituted, straight-chain or branched C₁-C₁₂ alkyl group. In some embodiments, alkyl refers to a C₁-C₆ alkyl group. Exemplary alkyl groups include methyl, ethyl, propyl, *iso*-propyl, *n*-butyl, *iso*-butyl, *tert*-butyl, *sec*-butyl, *n*-pentyl, *n*-hexyl, *n*-heptyl, and *n*-octyl. Substituted alkyl groups provided herein are substituted by one or more substituents selected from the group consisting of halogen, cyano, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, C₃-C₆ cycloalkyl, phenyl, OH, CO₂H, CO₂(C₁-C₄ alkyl), NH₂, NH(C₁-C₄ alkyl), N(C₁-C₄ alkyl)₂, NH(C=O)C₁-C₄ alkyl, (C=O)NH(C₁-C₄ alkyl), (C=O)N(C₁-C₄ alkyl)₂, S(C₁-C₄ alkyl), SO(C₁-C₄ alkyl), SO₂(C₁-C₄ alkyl), SO₂NH(C₁-C₄ alkyl), SO₂N(C₁-C₄ alkyl)₂, and NHSO₂(C₁-C₄ alkyl). In some embodiments, the substituted alkyl group has 1 or 2 substituents. In some embodiments, the alkyl group is unsubstituted.

1. A compound of formula (I):



R^A is selected from the group consisting of:



R¹ is selected from the group consisting of hydrogen, deuterio, fluoro, hydroxyl, cyano, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, C₁-C₆ haloalkoxy, C₁-C₆ alkyl substituted with one (R^N)₂N substituent, C₁-C₆ cyanoalkyl, C₁-C₆ alkylsulfonyl, phenyl, benzyl, 4 to 6 membered heterocyclyl, and 5 to 6 membered heteroaryl;

wherein, when R¹ is phenyl, benzyl, C₁-C₆ alkyl, C₁-C₆ alkoxy or C₃-C₆ cycloalkyl, the phenyl ring of the phenyl or the benzyl, the alkyl of the C₁-C₆ alkyl or the C₁-C₆ alkoxy, or the cycloalkyl ring of the C₃-C₆ cycloalkyl is optionally substituted with 1 to 2 substituents selected from the group consisting of fluoro, chloro, cyano, C₁-C₃ alkyl, cyclopropyl, C₁-C₃ alkoxy, C₁-C₃ hydroxyalkyl, C₁-C₃ haloalkyl, C₁-C₆ alkoxycarbonyl, C₁-C₃ alkoxy-C₁-C₃ alkyl and C₁-C₃ haloalkoxy;

R^{2a} and R^{2b} are each independently selected from the group consisting of hydrogen, deuterio, fluoro, hydroxyl, C₁-C₃ alkyl, and C₁-C₃ fluoroalkyl; provided that both R^{2a} and R^{2b} cannot be hydroxyl; or


R¹ is selected from the group consisting of hydrogen, deuterio, fluoro, methyl, and cyano; and

R^{2a} and R^{2b} together with the carbon atom to which they are both attached form a 4 to 6 membered heterocyclic ring or a 3 to 5 membered carbocyclic ring, each optionally substituted by 1 to 2 substituents selected from the group consisting of fluoro, chloro, hydroxyl, cyano, C₁-C₃ alkyl, hydroxymethyl, methoxymethyl, C₁-C₄ alkoxycarbonyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy;

each R^N is independently selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkyl; or two R^N together with the nitrogen atom to which they are both attached form a 4-6 membered heterocyclic ring;

each R⁶ is independently selected from the group consisting of hydrogen, halogen, C₁-C₆ alkyl, C₃-C₆ cycloalkyl, C₁-C₃ cyanoalkyl, C₁-C₃ alkylcarbonyl, C₁-C₃ methylsulfonyl, C₁-C₆ alkoxy, C₁-C₆ haloalkyl, formyl, C₁-C₆ haloalkoxy, cyano, 1-methyl-pyrazol-4-yl and pyrimidinyl;

the A ring, the B ring, R^{B1}, R^{B2}, q and p together are selected from the group consisting of:




R^{3a} and R^{3b} are selected as follows:

one of R^{3a} and R^{3b} is H, and the other is selected from the group consisting of hydrogen, deuterio, fluoro, chloro, hydroxyl, cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy; or


each of R^{3a} and R^{3b} is independently selected from the group consisting of deuterio, fluoro, chloro, hydroxyl, cyano, and methyl, provided that R^{3a} and R^{3b} cannot both be OH or CN; or

R^{3a} and R^{3b}, together with the carbon atom to which they are both attached, form 1,1-cyclopropylene; and

R⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl, phenyl, benzyl, CH₂-(C₃-C₆ cycloalkyl), CH₂CH₂-(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl), CH₂CH₂-(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH₂-(5 to 6 membered heteroaryl); wherein when a phenyl ring or a 5 to 6 membered heteroaryl is present it may be substituted by 1 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano;

provided that, when R^A is  and R^{2a} and R^{2b} are each hydrogen, R¹ is not hydrogen, halogen or methyl.

2. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein: the A ring, the B ring, R^{B1}, R^{B2}, q and p together are:



R^{3a} and R^{3b} are selected as follows:


one of R^{3a} and R^{3b} is H, and the other is selected from the group consisting of hydrogen, deuterio, fluoro, chloro, hydroxyl, cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy; or

each of R^{3a} and R^{3b} is independently selected from the group consisting of deuterio, fluoro, chloro, hydroxyl, cyano, and methyl, provided that R^{3a} and R^{3b} cannot both be OH or CN; or

R^{3a} and R^{3b}, together with the carbon atom to which they are both attached, form 1,1-cyclopropylene; and

R⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₃-C₆ cycloalkyl, C₁-C₆ alkoxy, C₁-C₆ haloalkoxy, C₁-C₆ thioalkyl, phenyl, benzyl, CH₂-(C₃-C₆ cycloalkyl), CH₂CH₂-(C₃-C₆ cycloalkyl), CH₂-(4 to 6 membered heterocyclyl), CH₂CH₂-(4 to 6 membered heterocyclyl), 5 to 6 membered heteroaryl, and CH₂-(5 to 6 membered heteroaryl); wherein when a phenyl ring or a 5 to 6 membered heteroaryl is present it may be substituted by 1 to 3 substituents selected from the group consisting of halogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₁-C₄ alkoxy, C₁-C₄ haloalkoxy, and cyano.

3. A compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein the A ring, the B ring, R^{B1}, R^{B2}, q and p together are selected from the group consisting of:



wherein:

R^{3a} and R^{3b} are selected as follows:

one of R^{3a} and R^{3b} is H, and the other is selected from the group consisting of hydrogen, deuterio, fluoro, chloro, hydroxyl, cyano, C₁-C₄ alkyl, C₁-C₄ haloalkyl, cyclopropyl, C₁-C₄ alkoxy and C₁-C₄ haloalkoxy; or


each of R^{3a} and R^{3b} is independently selected from the group consisting of deuterio, fluoro, chloro, hydroxyl, cyano, and methyl, provided that R^{3a} and R^{3b} cannot both be OH or CN; or

R^{3a} and R^{3b} , together with the carbon atom to which they are both attached, form 1,1-cyclopropylene; and

each R^5 is independently selected from the group consisting of H, F, Cl, C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy; and

m is 0, 1, 2 or 3.

4. A compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein the A ring, the B ring, R^{B1} , R^{B2} , q and p together are:




wherein:

each R^5 is selected from the group consisting of hydrogen, fluoro, chloro C₁-C₆ alkyl, C₁-C₆ haloalkyl, C₁-C₆ alkoxy, and C₁-C₆ haloalkoxy; and

m is 0, 1, 2 or 3.

5. A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the A ring, the B ring, R^{B1} , R^{B2} , q and p together are:



wherein:

each R^5 is selected from the group consisting of hydrogen, fluoro, chloro C_1 - C_6 alkyl, C_1 - C_6 haloalkyl, C_1 - C_6 alkoxy, and C_1 - C_6 haloalkoxy; and

m is 0, 1, 2 or 3.

6. A compound of claim 3, 4 or 5, or a pharmaceutically acceptable salt thereof, wherein R^5 is selected from the group consisting of H, F, Cl, CH_3 , CH_2CH_3 , OCH_3 , CF_3 , OCF_3 , CF_2H , and OCF_2H .


7. A compound of any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is selected from the group consisting of hydrogen, fluoro, hydroxyl, cyano, CH_2CN , C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, C_1 - C_6 alkoxy, C_1 - C_6 haloalkyl, C_1 - C_6 haloalkoxy, and 4 to 5 membered heterocyclyl; and


R^{2a} and R^{2b} are each independently selected from the group consisting of hydrogen, deuterio, fluoro, hydroxyl, C_1 - C_3 alkyl, and C_1 - C_3 fluoroalkyl, provided that, when R^{2a} and R^{2b} are each hydrogen, R^1 is not hydrogen, halogen or methyl; or


R^1 is hydrogen, deuterio, fluoro, methyl or cyano, and R^{2a} and R^{2b} , together with the carbon atom to which they are both attached, form 1,1-cyclopropylene that is optionally substituted by one or two substituents selected from the group consisting of F, C_{1-3} alkyl, hydroxyl, hydroxymethyl, methoxymethyl, cyano, CO_2 - C_{1-3} alkyl, trifluoromethyl, difluoromethoxy, and trifluoromethoxy.

8. A compound of any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof





9. A compound of claim 8, or a pharmaceutically acceptable salt thereof,





10. A compound of claim 8, or a pharmaceutically acceptable salt thereof,

wherein R^1  is selected from the group consisting of:



11. A compound of any of claims 1 to 10, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

cis-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-ol;

cis-2-(1,1-difluoropropyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

cis-7-fluoro-2-(1-fluoropropyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

cis-2,2,2-trifluoro-1-(7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)ethanol;

cis-2-[cyclopropyl(difluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

cis-7-fluoro-2-(1-fluoro-1-methyl-propyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(1R)-1-fluoropropyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-[(S)-1-fluoropropyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

cis-2-(1,1-difluoro-2,2-dimethyl-propyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

cis-7-fluoro-5-phenyl-2-propyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 cis-2-cyclopropyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 cis-7-fluoro-5-phenyl-2-(trifluoromethyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-2-[cyclopropyl(difluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-7-fluoro-5-phenyl-2-propyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5R,7R)-7-fluoro-5-phenyl-2-(3,3,3-trifluoropropyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 trans-2-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]cyclopropanecarbonitrile;
 (5S,7S)-2-[difluoro-(3-methyloxetan-3-yl)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-7-fluoro-5-phenyl-2-(3,3,3-trifluoropropyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-7-fluoro-2-(1-methylpyrazol-3-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-2-[(2,2-difluorocyclopropyl)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 ethyl rac-(1R,2R)-2-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]cyclopropanecarboxylate;
 3-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propanenitrile;
 (5S,7S)-2-[difluoro-[rac-(1R,2R)-2-fluorocyclopropyl]methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-7-fluoro-5-phenyl-2-[rac-(1R,2R)-2-(methoxymethyl)cyclopropyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-7-fluoro-2-(4-methylpyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S)-5-(2-fluorophenyl)-2-propyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-7-fluoro-2-((S)-2-fluorobutan-2-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-2-(2,2-difluorocyclopropyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-2-(3,3-difluoropropyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;
 (5S,7S)-2-(2,2-dimethylcyclopropyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-pyrazol-1-yl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-((R)-2-fluorobutan-2-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[2-(trifluoromethyl)cyclopropyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(S)-cyclopropyl-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanol;

(R)-cyclopropyl-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanol;

(5S,7S)-7-fluoro-2-(isopropoxymethyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-(2-ethoxyethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(4-isopropylpyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazole-4-carbaldehyde;

(5S,7S)-7-fluoro-5-phenyl-2-(4-pyrimidin-4-ylpyrazol-1-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-[1-bicyclo[1.1.1]pentanyl(difluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-(2-cyclopropylethynyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-prop-1-ynyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-((R)-bicyclo[1.1.1]pentan-1-ylfluoromethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-((S)-bicyclo[1.1.1]pentan-1-ylfluoromethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

1-[[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methyl]cyclopropanecarbonitrile;

2-fluoro-2-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]acetonitrile;

(5S,7S)-7-fluoro-2-[(E)-2-(1-methylpyrazol-4-yl)vinyl]-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-vinyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

2-[(rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methoxy]acetonitrile;

(5S,7S)-2-allyl-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazole-3-carbonitrile;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazole-4-carbonitrile;

3-[[[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methylene]cyclobutanecarbonitrile;

(5S,7S)-7-fluoro-5-phenyl-2-[4-(trifluoromethyl)pyrazol-1-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(4-methoxypyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(4-fluoropyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-(4-ethylpyrazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-(4-chloropyrazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(1-methylimidazol-2-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[4-(trifluoromethyl)imidazol-1-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(5-methylpyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[3-(trifluoromethyl)pyrazol-1-yl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

5-amino-1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-3-methylpyrazole-4-carbonitrile;

(5S,7S)-7-fluoro-2-imidazol-1-yl-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(2-methylimidazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-(1,2,4-triazol-1-yl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-(2-chloroimidazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-(4,5-dimethylimidazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-3-methylimidazol-2-one;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]indazole-4-carbonitrile;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]indazole;

(5S,7S)-7-fluoro-2-(5-methyl-1,2,4-triazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-(4-chloroimidazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(4-fluoroimidazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

2-[1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazol-4-yl]acetonitrile;

1-[1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazol-4-yl]ethanone;

(5S,7S)-2-(4-cyclopropylpyrazol-1-yl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(4-methylsulfonylpyrazol-1-yl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]benzotriazole;

5-chloro-1-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]benzotriazole;

3-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]triazolo[4,5-c]pyridine;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazolo[4,3-b]pyridine;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]benzotriazole-5-carbonitrile;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-4,5,6,7-tetrahydrobenzotriazole;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazolo[3,4-c]pyridine;

5-methyl-1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]benzotriazole;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]pyrazolo[4,3-c]pyridine;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]triazolo[4,5-c]pyridine;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-5-methyl-pyrazole-3-carbonitrile;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-3-methyl-pyrazole-4-carbonitrile;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]-5-methyl-pyrazole-4-carbonitrile;

(5S,7S)-2-(cyclobutylmethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(1S,2S)-2-methylcyclopropyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(1R,2R)-2-methylcyclopropyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(1-methylenepropyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S)-2-(cyclopropylmethyl)-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

4-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]isoxazole;

1-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]azetidine-3-carbonitrile;

(5S,7S)-2-[cyclopropyl(deuterio)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

2-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]acetonitrile;

2-methyl-2-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propanenitrile;

(5S,7S)-2-[cyclopropyl(difluoro)methyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(R)-(1-methylcyclopropyl)-[(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanol;

[rac-(1R,2S)-2-fluorocyclopropyl]-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanol;

(5S,7S)-7-fluoro-5-phenyl-2-[(R)-cyclopropyl(fluoro)methyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

[rac-(1S,2R)-2-fluorocyclopropyl]-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]methanol;

(5S,7S)-7-fluoro-5-phenyl-2-[(S)-cyclopropyl(fluoro)methyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(R)-cyclopropyl-deuterio-fluoro-methyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(S)-cyclopropyl-deuterio-fluoro-methyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

rac-(5S,7S)-2-[(2,2-difluorocyclopropyl)methyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(1S,2S)-2-[difluoro-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methyl]cyclopropanecarbonitrile;

(R)-cyclopropyl-[(4R,6R)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]methanol;

(S)-cyclopropyl-[(4R,6R)-4-fluoro-6-phenyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-2-yl]methanol;

(5S,7S)-2-[cyclopropyl(dideuterio)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

2,2-difluoro-1-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl]propan-1-ol; and ,

(5R,7R)-2-(difluoromethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.

12. A compound of any of claims 1 to 11, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

(1S,2S)-2-[difluoro-[rac-(5S,7S)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazol-2-yl)methyl]cyclopropanecarbonitrile;

(5S,7S)-2-(2-ethoxyethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-2-(isopropoxymethyl)-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

rac-(5S,7S)-2-[(2,2-difluorocyclopropyl)methyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-(cyclobutylmethyl)-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(S)-cyclopropyl(fluoro)methyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(R)-cyclopropyl(fluoro)methyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(S)-cyclopropyl-deuterio-fluoro-methyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(R)-cyclopropyl-deuterio-fluoro-methyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-[cyclopropyl(difluoro)methyl]-7-fluoro-5-(2-fluorophenyl)-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-[cyclopropyl(deuterio)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-2-[1-bicyclo[1.1.1]pentanyl(difluoro)methyl]-7-fluoro-5-phenyl-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole;

(5S,7S)-7-fluoro-5-phenyl-2-[(1S,2S)-2-methylcyclopropyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole; and,

(5S,7S)-7-fluoro-5-phenyl-2-[(1R,2R)-2-methylcyclopropyl]-6,7-dihydro-5H-pyrrolo[1,2-b][1,2,4]triazole.

13. A compound of claim 11, or a pharmaceutically acceptable salt thereof, having a RIP1 kinase inhibitory activity K_i of less than 100 nM.

14. A pharmaceutical composition comprising a compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition of claim 14, for use as a therapeutically active substance.


16. A compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition of claim 14, for use in the treatment of a disease or disorder selected from the group consisting of Parkinson's Disease, Lewy body dementia, multiple system atrophy, Parkinson-plus syndrome, tauopathy, Alzheimer's Disease, frontotemporal dementia, amyotrophic lateral sclerosis, spinal muscular atrophy, primary lateral sclerosis, Huntington's disease, ischemia, stroke, intracranial hemorrhage, cerebral hemorrhage, muscular dystrophy, progressive muscular atrophy, pseudobulbar palsy, progressive bulbar palsy, spinal muscular atrophy, inherited muscular atrophy, peripheral neuropathy, progressive supranuclear palsy, corticobasal degeneration, and demyelinating disease.

17. The use of a compound of any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof, or pharmaceutical composition of claim 14, in the preparation of a medicament for the treatment of a disease or disorder selected from the group consisting of Parkinson's Disease, Lewy body dementia, multiple system atrophy, Parkinson-plus syndrome, tauopathy, Alzheimer's Disease, frontotemporal dementia, amyotrophic lateral sclerosis, spinal muscular atrophy, primary lateral sclerosis, Huntington's disease, ischemia, stroke, intracranial hemorrhage, cerebral hemorrhage, muscular dystrophy, progressive muscular atrophy, pseudobulbar palsy, progressive bulbar palsy, spinal muscular atrophy, inherited muscular atrophy, peripheral neuropathy, progressive supranuclear palsy, corticobasal degeneration, and demyelinating disease.

18. The use of claim 17, wherein the disease or disorder is Alzheimer's disease.

19. The use of claim 17, wherein the disease or disorder is multiple sclerosis.

20. The use of claim 17, wherein the disease or disorder is Parkinson's disease.
21. The use of claim 17, wherein the disease or disorder is amyotrophic lateral sclerosis.
22. The use of claim 17, wherein the disease or disorder is Huntington's disease.
23. The use of claim 17, wherein the disease or disorder is spinal muscular atrophy.
24. A compound of formula (II):



or pharmacologically acceptable salt thereof.